Build Your Comparison

Side-by-side financial analysis
NCRA logo
NCRA
LIXT logo
LIXT
ONCY logo
ONCY
RELI logo
RELI
IMVT logo
IMVT
JPM logo
JPM
Try popular comparisons:

Stock Comparison

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NCRA
Nocera, Inc.

Packaged Foods

Consumer DefensiveNASDAQ • TW
Market Cap$2M
5Y Perf.-96.3%
LIXT
Lixte Biotechnology Holdings, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$76M
5Y Perf.-77.0%
ONCY
Oncolytics Biotech Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$94M
5Y Perf.-66.6%
RELI
Reliance Global Group, Inc.

Insurance - Brokers

Financial ServicesNASDAQ • US
Market Cap$554K
5Y Perf.-100.0%
IMVT
Immunovant, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$6.39B
5Y Perf.-20.3%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$842.21B
5Y Perf.+142.8%

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NCRA logoNCRA
LIXT logoLIXT
ONCY logoONCY
RELI logoRELI
IMVT logoIMVT
JPM logoJPM
IndustryPackaged FoodsBiotechnologyBiotechnologyInsurance - BrokersBiotechnologyBanks - Diversified
Market Cap$2M$76M$94M$554K$6.39B$842.21B
Revenue (TTM)$11M$0.00$0.00$13M$0.00$270.79B
Net Income (TTM)$-4M$-7M$-35M$-7M$-506M$58.03B
Gross Margin1.4%-14.5%58.6%
Operating Margin-25.2%-66.3%27.7%
Forward P/E14.0x
Total Debt$7M$664K$773K$13M$72K$751.15B
Cash & Equiv.$8M$5M$7M$373K$902M$469.32B

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NCRA
LIXT
ONCY
RELI
IMVT
JPM
StockJan 21Jun 26Return
Nocera, Inc. (NCRA)1003.7-96.3%
Lixte Biotechnology… (LIXT)10023.0-77.0%
Oncolytics Biotech … (ONCY)10033.4-66.6%
Reliance Global Gro… (RELI)1000.0-100.0%
Immunovant, Inc. (IMVT)10079.7-20.3%
JPMorgan Chase & Co. (JPM)100242.8+142.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 4 of 7 categories (6-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Lixte Biotechnology Holdings, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. RELI also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NCRA
Nocera, Inc.
The Consumer Defensive Pick

NCRA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer defensive exposure
LIXT
Lixte Biotechnology Holdings, Inc.
The Defensive Pick

LIXT is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.19, Low D/E 6.1%, current ratio 3.88x
  • Beta 1.19, current ratio 3.88x
  • 152.8% revenue growth vs ONCY's -65.0%
  • +407.2% vs NCRA's -83.7%
Best for: sleep-well-at-night and defensive
ONCY
Oncolytics Biotech Inc.
The Healthcare Pick

Among these 6 stocks, ONCY doesn't own a clear edge in any measured category.

Best for: healthcare exposure
RELI
Reliance Global Group, Inc.
The Insurance Pick

RELI ranks third and is worth considering specifically for value.

  • Better valuation composite
Best for: value
IMVT
Immunovant, Inc.
The Healthcare Pick

IMVT doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: healthcare exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 15 yrs, beta 0.95, yield 1.6%
  • Rev growth 14.6%, EPS growth 21.7%
  • 435.6% 10Y total return vs IMVT's 212.7%
  • 21.6% margin vs RELI's -53.4%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthLIXT logoLIXT152.8% revenue growth vs ONCY's -65.0%
ValueRELI logoRELIBetter valuation composite
Quality / MarginsJPM logoJPM21.6% margin vs RELI's -53.4%
Stability / SafetyJPM logoJPMBeta 0.95 vs NCRA's 1.68, lower leverage
DividendsJPM logoJPM1.6% yield; 15-year raise streak; the other 5 pay no meaningful dividend
Momentum (1Y)LIXT logoLIXT+407.2% vs NCRA's -83.7%
Efficiency (ROA)JPM logoJPM1.3% ROA vs ONCY's -275.4%

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NCRANocera, Inc.

Segment breakdown not available.

LIXTLixte Biotechnology Holdings, Inc.

Segment breakdown not available.

ONCYOncolytics Biotech Inc.

Segment breakdown not available.

RELIReliance Global Group, Inc.
FY 2020
Property and Casualty
100.0%$1M
IMVTImmunovant, Inc.

Segment breakdown not available.

JPMJPMorgan Chase & Co.
FY 2024
Consumer & Community Banking
40.3%$71.5B
Commercial And Investment Bank
39.5%$70.1B
Asset and Wealth Management Segment
12.2%$21.6B
Segment Reporting, Reconciling Item, Corporate Nonsegment
9.8%$17.4B
Segment Reconciling Items
-1.7%$-3,037,000,000

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGIMVT

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 4 of 6 comparable metrics.

JPM and IMVT operate at a comparable scale, with $270.8B and $0 in trailing revenue. JPM is the more profitable business, keeping 21.6% of every revenue dollar as net income compared to RELI's -53.4%. On growth, RELI holds the edge at -27.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$11M$0$0$13M$0$270.8B
EBITDAEarnings before interest/tax-$3M-$7M-$31M-$7M-$532M$81.3B
Net IncomeAfter-tax profit-$4M-$7M-$35M-$7M-$506M$58.0B
Free Cash FlowCash after capex-$3M-$4M-$29M-$2M-$407M-$119.7B
Gross MarginGross profit ÷ Revenue+1.4%-14.5%+58.6%
Operating MarginEBIT ÷ Revenue-25.2%-66.3%+27.7%
Net MarginNet income ÷ Revenue-34.0%-53.4%+21.6%
FCF MarginFCF ÷ Revenue-26.9%-18.1%-15.5%
Rev. Growth (YoY)Latest quarter vs prior year-49.8%-27.5%
EPS Growth (YoY)Latest quarter vs prior year-3.9%+37.9%-39.2%+70.1%-14.1%+16.0%
JPM leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

RELI leads this category, winning 2 of 3 comparable metrics.
MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$2M$76M$94M$553,552$6.4B$842.2B
Enterprise ValueMkt cap + debt − cash$2M$72M$89M$13M$5.5B$1.12T
Trailing P/EPrice ÷ TTM EPS-0.84x-5.56x-2.83x-0.03x-11.23x15.82x
Forward P/EPrice ÷ next-FY EPS est.14.03x
PEG RatioP/E ÷ EPS growth rate1.22x
EV / EBITDAEnterprise value multiple13.54x
Price / SalesMarket cap ÷ Revenue0.22x0.04x3.11x
Price / BookPrice ÷ Book value/share1.09x30.91x0.08x6.66x2.61x
Price / FCFMarket cap ÷ FCF
RELI leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

JPM leads this category, winning 6 of 9 comparable metrics.

JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-102 for ONCY. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RELI's 4.35x. On the Piotroski fundamental quality scale (0–9), JPM scores 5/9 vs ONCY's 1/9, reflecting solid financial health.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-132.0%-113.2%-102.5%-181.4%-68.2%+16.1%
ROA (TTM)Return on assets-52.5%-96.3%-2.8%-41.3%-62.2%+1.3%
ROICReturn on invested capital-70.0%-121.5%-32.0%+5.4%
ROCEReturn on capital employed-35.9%-83.5%-5.1%-45.9%-68.3%+8.2%
Piotroski ScoreFundamental quality 0–9341425
Debt / EquityFinancial leverage3.31x0.06x4.35x0.00x2.18x
Net DebtTotal debt minus cash-$697,307-$4M-$6M$13M-$902M$281.8B
Cash & Equiv.Liquid assets$8M$5M$7M$372,695$902M$469.3B
Total DebtShort + long-term debt$7M$664,491$772,509$13M$72,000$751.1B
Interest CoverageEBIT ÷ Interest expense-1217.29x-4.90x0.74x
JPM leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in IMVT five years ago would be worth $30,500 today (with dividends reinvested), compared to $3 for RELI. Over the past 12 months, LIXT leads with a +407.2% total return vs NCRA's -83.7%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.0% vs RELI's -84.8% — a key indicator of consistent wealth creation.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-80.3%+82.3%-14.7%-54.3%+20.1%-3.1%
1-Year ReturnPast 12 months-83.7%+407.2%+151.3%-81.7%+94.2%+21.5%
3-Year ReturnCumulative with dividends-88.7%+5.6%-49.0%-99.6%+48.3%+135.5%
5-Year ReturnCumulative with dividends-96.6%-77.3%-72.0%-100.0%+205.0%+102.5%
10-Year ReturnCumulative with dividends-97.4%-22.2%-79.6%-100.0%+212.7%+435.6%
CAGR (3Y)Annualised 3-year return-51.6%+1.8%-20.1%-84.8%+14.0%+33.0%
JPM leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LIXT and JPM each lead in 1 of 2 comparable metrics.

JPM is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than NCRA's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIXT currently trades 93.3% from its 52-week high vs RELI's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.68x1.19x1.24x1.35x1.67x0.95x
52-Week HighHighest price in past year$2.40$7.50$1.51$3.55$36.27$337.25
52-Week LowLowest price in past year$0.16$0.64$0.33$0.15$14.32$260.31
% of 52W HighCurrent price vs 52-week peak+7.0%+93.3%+55.4%+6.9%+85.8%+92.6%
RSI (14)Momentum oscillator 0–10040.869.846.242.958.358.4
Avg Volume (50D)Average daily shares traded7.2M89K1.3M2.9M1.9M7.1M
Evenly matched — LIXT and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ONCY as "Buy", IMVT as "Buy", JPM as "Buy". Consensus price targets imply 40.4% upside for IMVT (target: $44) vs 8.5% for JPM (target: $339). JPM is the only dividend payer here at 1.64% yield — a key consideration for income-focused portfolios.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…IMVT logoIMVTImmunovant, Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$43.67$338.78
# AnalystsCovering analysts102361
Dividend YieldAnnual dividend ÷ price+1.6%
Dividend StreakConsecutive years of raises0015
Dividend / ShareAnnual DPS$5.13
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%0.0%+3.4%
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

JPM leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RELI leads in 1 (Valuation Metrics). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

NCRA vs LIXT vs ONCY vs RELI vs IMVT vs JPM: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is NCRA or LIXT or ONCY or RELI or IMVT or JPM a better buy right now?

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 14. 6% revenue growth year-over-year, versus -35. 2% for Nocera, Inc. (NCRA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 8x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Oncolytics Biotech Inc. (ONCY) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — NCRA or LIXT or ONCY or RELI or IMVT or JPM?

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +205. 0%, compared to -100. 0% for Reliance Global Group, Inc. (RELI). Over 10 years, the gap is even starker: JPM returned +435. 6% versus RELI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — NCRA or LIXT or ONCY or RELI or IMVT or JPM?

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 95β versus Nocera, Inc. 's 1. 68β — meaning NCRA is approximately 77% more volatile than JPM relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for Reliance Global Group, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — NCRA or LIXT or ONCY or RELI or IMVT or JPM?

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 14. 6% versus -35. 2% for Nocera, Inc. (NCRA). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 21. 7% year-over-year, compared to -11. 1% for Nocera, Inc.. Over a 3-year CAGR, RELI leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — NCRA or LIXT or ONCY or RELI or IMVT or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 21. 6% net margin versus -64. 5% for Reliance Global Group, Inc. — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 27. 7% versus -54. 8% for RELI. At the gross margin level — before operating expenses — JPM leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is NCRA or LIXT or ONCY or RELI or IMVT or JPM more undervalued right now?

Analyst consensus price targets imply the most upside for IMVT: 40.

4% to $43. 67.

07

Which pays a better dividend — NCRA or LIXT or ONCY or RELI or IMVT or JPM?

In this comparison, JPM (1.

6% yield) pays a dividend. NCRA, LIXT, ONCY, RELI, IMVT do not pay a meaningful dividend and should not be held primarily for income.

08

Is NCRA or LIXT or ONCY or RELI or IMVT or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 6% yield, +435. 6% 10Y return). Nocera, Inc. (NCRA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +435. 6%, NCRA: -97. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between NCRA and LIXT and ONCY and RELI and IMVT and JPM?

These companies operate in different sectors (NCRA (Consumer Defensive) and LIXT (Healthcare) and ONCY (Healthcare) and RELI (Financial Services) and IMVT (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NCRA is a small-cap quality compounder stock; LIXT is a small-cap quality compounder stock; ONCY is a small-cap quality compounder stock; RELI is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NCRA, LIXT, ONCY, RELI, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.